Andrew Cheng
CIK 1778307 · President and CEO · last filed 2026-05-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$599.1K
Companies
3
Total Filings
82
Lifetime Open-Market Net
-$43.39M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Recent Filings · Page 5 of 9
82 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-07-06 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$963.0K | EDGAR |
| 2023-06-27 | Akero Therapeutics, Inc. (AKRO) Delisted | Exer (M) | +40,000 | $24.6K | EDGAR |
| 2023-06-15 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −1,613 | -$89.0K | EDGAR |
| 2023-06-05 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$1.09M | EDGAR |
| 2023-05-12 | VERA | Grant (A) | — | $0 | EDGAR |
| 2023-05-03 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | +40,000 | -$1.09M | EDGAR |
| 2023-04-05 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$933.2K | EDGAR |
| 2023-03-14 | Akero Therapeutics, Inc. (AKRO) Delisted | Tax (F) | −1,706 | -$74.2K | EDGAR |
| 2023-03-03 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$1.15M | EDGAR |
| 2023-02-03 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$1.21M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.